EGRX Stock — Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc (EGRX)

Updated October 16, 2026.

EGRX is a Stock. Total return is -93.1% over the past 12.7 years, 511.8 points behind SPY at 418.7%.

Eagle Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes medications for central nervous system disorders, critical care, and oncology, with an approved product portfolio including treatments for malignant hyperthermia, certain blood cancers, lung cancer, postoperative nausea, and procedural sedation, along with several candidates in development. The company does not currently have a stated distribution frequency or known dividend practice. This security may appeal to investors seeking exposure to specialty pharmaceutical development and commercialization rather than income generation.

EGRX performance versus SPY

Price and return data through 2026-10-16.

Total return is -93.1% over the past 12.7 years, 511.8 points behind SPY at 418.7%. Over the past year its total return — price change plus distributions reinvested — is -41.0%. Its deepest 1-year drawdown was 99.9%.

EGRX key facts

Asset type

Stock

Asset class

Equity

Inception date

02/12/2014

Distribution frequency

None

Last close

$0.89 (as of 2026-10-16)

Market cap

$11,644,434

Average volume

4910.0

Beta

0.871

Payout ratio

0.0%

P/E ratio

0.5

Forward P/E

11.3379

EPS

$1.77

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

EGRX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 99.9%.

Who may consider EGRX — and who may not

It is a weaker fit for investors who need monthly cash flow (EGRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on EGRX

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions